Invo BioScience (INVO)
(Delayed Data from NSDQ)
$1.06 USD
+0.08 (8.16%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $1.03 -0.03 (-2.83%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
INVO 1.06 +0.08(8.16%)
Will INVO be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for INVO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for INVO
MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Misses Revenue Estimates
Clovis Oncology (CLVS) Reports Q3 Loss, Lags Revenue Estimates
INVO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Regenxbio (RGNX) Reports Q3 Loss, Lags Revenue Estimates
Invo BioScience Inc. (INVO) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Invo BioScience Inc. (INVO) Upgraded to Buy: Here's What You Should Know
Other News for INVO
12 Health Care Stocks Moving In Thursday's Intraday Session
Bio-Path Holdings, Sunshine Biopharma, INVO Bioscience among healthcare movers
SBFM, BPTH and INDO among pre-market losers
Predictive Oncology, BIMI Holdings, IMAC Holdings among healthcare movers
LI, VERU and MRIN among pre-market losers